Delivery Order SPE2DB22D3010-SPE2DB25FP3EY
- Not listed
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,350.64 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $10,970.04 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-competitive set-aside contract. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract valued at $4,825.70. This non-set-aside delivery order, awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $16,119.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3EYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets in 30-count units under a firm fixed price contract, with a ceiling value of $27,725.81. The award was issued on August 14, 2025, with an ultimate completion date of August 15, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive range of pharmaceutical products to military and veteran healthcare systems. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to fulfill medical supply requirements across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard, demonstrating the company's critical role in sustaining military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.7k | 8/14/25 |